{"filing":{"accession_number":"0001193125-26-305467","cik":"0001213037","ticker":"CRDF","company_name":"Cardiff Oncology, Inc.","form":"8-K","filing_date":"2026-07-16","report_date":null,"primary_document":"crdf-20260714.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1213037/000119312526305467/crdf-20260714.htm"},"events":[{"id":18314,"run_id":16461,"accession_number":"0001193125-26-305467","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Cardiff Oncology completed a registered direct offering of approximately 8.6 million shares of common stock and accompanying warrants at $1.05 per share, with officers and directors purchasing an additional ~731,707 insider shares at $1.435 per share, generating approximately $10.05 million in gross proceeds for working capital and general corporate purposes.","company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","filing_date":"2026-07-16","form":"8-K","submitted_at":null,"items":[{"id":17085,"accession_number":"0001193125-26-305467","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Cardiff Oncology entered into a securities purchase agreement to sell 8,571,429 shares of common stock and accompanying warrants at $1.05 per share, plus an additional 721,649 insider shares at $1.455 per share, generating approximately $10.05 million in gross proceeds. This is a registered direct offering of equity securities with warrants, representing a dilutive issuance to existing shareholders. The transaction closed on July 16, 2026, and the company intends to use net proceeds for working capital and general corporate purposes.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T12:39:39.794333+00:00","company_name":"","ticker":null,"filing_date":""},{"id":17086,"accession_number":"0001193125-26-305467","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Cardiff Oncology announced a registered direct offering of 8.6 million shares of common stock and accompanying warrants at $1.05 per share, with officers and directors purchasing an additional 731,707 shares at $1.435 per share, generating approximately $10 million in gross proceeds. This is a classic dilutive equity issuance under a shelf registration statement, material to investors as it increases share count and dilutes existing shareholders while raising capital for working capital and general corporate purposes.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T12:39:39.794333+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17085,"accession_number":"0001193125-26-305467","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Cardiff Oncology entered into a securities purchase agreement to sell 8,571,429 shares of common stock and accompanying warrants at $1.05 per share, plus an additional 721,649 insider shares at $1.455 per share, generating approximately $10.05 million in gross proceeds. This is a registered direct offering of equity securities with warrants, representing a dilutive issuance to existing shareholders. The transaction closed on July 16, 2026, and the company intends to use net proceeds for working capital and general corporate purposes.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T12:39:39.794333+00:00","company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","filing_date":"2026-07-16"},{"id":17086,"accession_number":"0001193125-26-305467","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Cardiff Oncology announced a registered direct offering of 8.6 million shares of common stock and accompanying warrants at $1.05 per share, with officers and directors purchasing an additional 731,707 shares at $1.435 per share, generating approximately $10 million in gross proceeds. This is a classic dilutive equity issuance under a shelf registration statement, material to investors as it increases share count and dilutes existing shareholders while raising capital for working capital and general corporate purposes.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T12:39:39.794333+00:00","company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","filing_date":"2026-07-16"}]}